CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies

Trial Profile

CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Leukaemia; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jul 2016 Number of treatment arms has been changed from 2 to 1 and the treatment will be administered as a single group assignment.
    • 18 Dec 2015 Planned primary completion date changed from 1 Feb 2022 to 1 Dec 2021, as reported by ClinicalTrials.gov.
    • 11 Dec 2015 Status changed from not yet recruiting to recruiting, according to a ZIOPHARM Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top